
|Articles|September 16, 2015
Adverse Event Reporting by HCPs Problematic
An analysis of 10.2 million adverse report records filed with the FDA along with survey of 123 health professionals by Tufts CSDD, found voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient.
Advertisement
An analysis of 10.2 million adverse report records filed with the FDA along with survey of 123 health professionals by Tufts CSDD, found voluntary adverse drug event (ADE) reporting in the United States is incomplete, inaccurate, and inefficient.
Key findings from the studies, reported in the September/October
- Pharmacists are more aggressive about ADE reporting, compared to nurses and physicians.
- ADE reports submitted by patients tend to be more complete than reports submitted by health care professionals.
- Completeness and accuracy of ADE reports vary by therapeutic area, with those for CNS drugs posting the highest drug name accuracy and some of the lowest lot number completion rates.
Read the
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
Breaking the Efficacy Ceiling in IBD and Beyond
4
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
5




